Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists
BACKGROUND: Little is known about physician perceptions of and practices in using infliximab – a biological agent that was approved in Canada for the treatment of Crohn’s disease in 2001, and for ulcerative colitis in 2006.
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Canadian Journal of Gastroenterology |
| Online Access: | http://dx.doi.org/10.1155/2011/837847 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560490384982016 |
|---|---|
| author | J Jones R Panaccione ML Russell R Hilsden |
| author_facet | J Jones R Panaccione ML Russell R Hilsden |
| author_sort | J Jones |
| collection | DOAJ |
| description | BACKGROUND: Little is known about physician perceptions of and practices in using infliximab – a biological agent that was approved in Canada for the treatment of Crohn’s disease in 2001, and for ulcerative colitis in 2006. |
| format | Article |
| id | doaj-art-c2577c537f18471fb5cdf745344054ca |
| institution | Kabale University |
| issn | 0835-7900 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Gastroenterology |
| spelling | doaj-art-c2577c537f18471fb5cdf745344054ca2025-02-03T01:27:29ZengWileyCanadian Journal of Gastroenterology0835-79002011-01-01251056556910.1155/2011/837847Medical Management of Inflammatory Bowel Disease among Canadian GastroenterologistsJ Jones0R Panaccione1ML Russell2R Hilsden3Departments of Medicine and Community Health and Epidemiology, University of Saskatchewan, Saskatoon, Saskatchewan, CanadaDepartment of Medicine, University of Calgary, Calgary, Alberta, CanadaDepartment of Community Health Sciences, University of Calgary, Calgary, Alberta, CanadaDepartment of Medicine, University of Calgary, Calgary, Alberta, CanadaBACKGROUND: Little is known about physician perceptions of and practices in using infliximab – a biological agent that was approved in Canada for the treatment of Crohn’s disease in 2001, and for ulcerative colitis in 2006.http://dx.doi.org/10.1155/2011/837847 |
| spellingShingle | J Jones R Panaccione ML Russell R Hilsden Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists Canadian Journal of Gastroenterology |
| title | Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists |
| title_full | Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists |
| title_fullStr | Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists |
| title_full_unstemmed | Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists |
| title_short | Medical Management of Inflammatory Bowel Disease among Canadian Gastroenterologists |
| title_sort | medical management of inflammatory bowel disease among canadian gastroenterologists |
| url | http://dx.doi.org/10.1155/2011/837847 |
| work_keys_str_mv | AT jjones medicalmanagementofinflammatoryboweldiseaseamongcanadiangastroenterologists AT rpanaccione medicalmanagementofinflammatoryboweldiseaseamongcanadiangastroenterologists AT mlrussell medicalmanagementofinflammatoryboweldiseaseamongcanadiangastroenterologists AT rhilsden medicalmanagementofinflammatoryboweldiseaseamongcanadiangastroenterologists |